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ABSTRACT: Speciﬁc therapeutic targeting of kidney podo-
cytes, the highly diﬀerentiated ramiﬁed glomerular cells
involved in the onset and/or progression of proteinuric
diseases, could become the optimal strategy for preventing
chronic kidney disease. With this aim, we developed a library
of engineered polymeric nanoparticles (NPs) of tuneable size
and surface properties and evaluated their interaction with
podocytes. NP cytotoxicity, uptake, and cytoskeletal eﬀects on
podocytes were ﬁrst assessed. On the basis of these data,
nanodelivery of dexamethasone loaded into selected biocom-
patible NPs was successful in repairing damaged podocytes.
Finally, a three-dimensional in vitro system of co-culture of
endothelial cells and podocytes was exploited as a new tool for
mimicking the mechanisms of NP interaction with glomerular cells and the repair of the kidney ﬁltration barrier.
■ INTRODUCTION
The study of the interaction of kidneys with nanoparticles
(NPs) is becoming an important area of research in
nanomedicine,1 particularly in the ﬁeld of nanotoxicology and
theragnostics.2−5
In the renal glomerulus, the ramiﬁed cells covering the
external side of the glomerular basement membrane, that is, the
podocytes, are the main gatekeeper of protein ﬁltration. When
podocytes work less eﬃciently due to stress or damage,
proteinuria, the loss of proteins in the urine, and glomerular
dysfunction inevitably take place. If not promptly treated, these
conditions lead to progression of glomerular damage and renal
failure.6
Several experimental results have suggested that most drugs
currently in use to treat or slow progression of glomerular
damage, such as steroids, immunosuppressive agents, and ACE-
inhibitors, have a direct action on podocytes.7−9
These therapies are charged by severe side eﬀects,
particularly when a systemic prolonged administration is
required. Therefore, the future development of a speciﬁc
podocyte-targeted nanodelivery system may represent a major
breakthrough in kidney disease research because it would
minimize dose and adverse drug reactions in current therapies
and promote the safe utilization of novel drugs directed against
speciﬁc molecular pathways activated during cell damage. In
addition, a deeper understanding of the mechanisms of the
interaction between podocytes and engineered NPs could be
beneﬁcial for developing new diagnostics of podocyte-
associated diseases.1
Although renal clearance and accumulation of NPs have been
the focus of recent studies,2,3 precise characterization of the
interaction between diﬀerent nanomaterials and glomerular
cells is still lacking. In the context of nanotoxicology, recent
reports have shown that administration of inorganic NPs (such
as nanosized silver and copper) to healthy rodents stimulated
morphological changes of primary and second podocyte
ramiﬁcations10 and induced apoptosis through oxidative stress
in vitro.11,12 On the other hand, in vivo evidence of inorganic
(iron oxide,13 gold14) NP uptake by podocytes without
aﬀecting kidney function was also reported. Quantum dots
functionalized with cyclo(RGD) peptide promoted selective
binding of ανβ3 integrin receptor on podocytes, followed by
internalization in vitro, in view of a possible application as
targeted therapy and diagnostics.1
The goal of this work was to develop in vitro models to
evaluate the interaction of engineered polymeric NPs with
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podocytes, aiming to (a) unveil fundamental mechanisms of
podocyte response to colloidal nanomaterials, depending on
the physicochemical characteristics of the NPs, and (b) design
new nanocarriers for potential targeted drug delivery to
podocytes in proteinuric diseases.
To fulﬁll our goals, a library of colloidal nanomaterials of
deﬁned size and surface chemistry was prepared. Poly(ε-
caprolactone)-based NPs of a narrow size distribution and
tunable size in the 30−120 nm range were synthesized
according to emulsion free radical polymerization techni-
ques.15−17 Bulk ring-opening polymerization of ε-caprolactone
with 2-hydroxyethyl methacrylate (HEMA) as an initiator was
ﬁrst carried out to produce biodegradable polyester-based
methacrylates, which were used as macromonomers in starved
Figure 1. (A) Sketch of the BEP and MSSEP methods used for the synthesis of polymeric NPs. (B) Chemical structure of the monomers/surfmers
used for the synthesis of NPs with diﬀerent sizes and surface properties (a). Transmission electron microscopy (TEM) images of NP9 (b) and NP10
(c) (scale bar 100 nm).
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semibatch emulsion polymerization (MSSEP) and batch
emulsion polymerization (BEP).15 With the optimal use of
polymerizable methacryloyl surfactants (i.e., positively, neg-
atively charged, PEGylated surfmers), the surface chemistry of
the NPs was also controlled (Figure 1).
In vitro assessment of the eﬀects of nanomaterials on
podocytes was carried out by testing NP cytotoxicity and
uptake, and cytoskeleton stress.
Possible podocyte repair by controlled drug nanodelivery was
then analyzed. Finally, we took advantage of a recently
developed 3D in vitro system based on a co-culture of
endothelial cells and podocytes,18,19 in mimicking the
mechanisms of NP interaction with glomerular cells and the
repair of the ﬁltration barrier.
■ RESULTS AND DISCUSSION
Library of Engineered Polymeric NPs. First, polyester-
based NPs were synthesized with controlled particle size and
surface properties, using emulsion free radical polymerization
techniques (Figure 1). Custom-made poly(ε-caprolactone)-
based macromonomer (HEMA-CL3) was co-polymerized with
suitable surfmers, namely, poly(ethylene glycol) methacrylate
(PEGMA), 3-sulfopropyl methacrylate potassium salt
(SPMAK), and methacrylate choline chloride (MACC), to
obtain neutral, negatively charged, and positively charged NPs,
respectively (Figure 1).
The HEMA-CL3 macromonomer was obtained through a
bulk ring-opening polymerization of ε-caprolactone, using
HEMA as the initiator, according to a recently developed
procedure.15
This hydrolyzable oligoester composed of three units of CL
was selected as the macromonomer because of its capability to
generate NPs with excellent biocompatibility, absence of
toxicity in vitro and in vivo,17,20 and a relatively fast degradation
kinetics.21−24
BEP was adopted as the standard polymerization procedure,
whereas MSSEP, in which the HEMA-CL3 macromonomer was
slowly fed into the reactor, was used to obtain smaller NPs
(Figure 1A). By changing the surfmer type and its weight ratio
to the HEMA-CL3 macromonomer, NP latexes were produced
with controlled size and surface charge. The average size,
polydispersity index (PDI), and Z-potential of the produced
NPs were evaluated via dynamic light scattering (DLS)
measurements and are reported in Table 1. Size distributions
are shown in Figure 2.
The synthesis conditions were chosen with the aim of
obtaining nearly monodisperse NPs with diﬀerent sizes for each
type of surface charge: a small average size between 30 and 40
nm, a medium one comprised between 60 and 70 nm, and a
larger one between 110 and 120 nm (Figure 2) to test whether
the particle size may inﬂuence the podocyte behavior in vitro.
Low hydrodynamic diameters were obtained by increasing
the amount of surfmer and using MSSEP.25 Small PEGylated
NPs (sample NP2, 40 nm) were obtained by using PEGMA
together with SDS as the surfactant because it was not possible
to obtain such a small average size with only a PEGylated
surfmer (Table 1). As expected, the PEGylated NPs produced
with only PEGMA showed a slightly negative Z-potential due
to the presence of sulfate groups from the free radical initiator
KPS, which are covalently attached to the polymers.26
Alternatively, by mixing PEGMA with either SPMAK or
MACC, weakly charged PEGylated NPs were also obtained
(NP1, negatively charged, 37 nm, and NP11, positively charged,
38 nm). NP1 presented mostly the same particle size as NP2,
with the advantage of avoiding the use of potentially toxic SDS
surfactant. NP11 instead was prepared with the aim of
exploiting the ability of positively charged groups to enhance
cellular uptake, while mitigating their typical cytotoxic behavior
with the shielding eﬀect of PEG chains.27
For these types of polymeric NPs, particle size and colloidal
stability remained unaltered during the in vitro biological tests,
as conﬁrmed by previous studies conducted in cell culture
media and physiological buﬀers.17,21
Cytotoxicity Tests. Cytotoxicity tests were ﬁrst carried out
to assess which polymeric NP has a safe/toxic eﬀect on
podocytes, depending on the size, surface properties, and
concentration. SV1 cells were cultured at 37 °C with a medium
containing diﬀerent concentrations of NPs (0.01−2 mg/mL)
for 24 h. Lactate dehydrogenase (LDH) colorimetric assay was
used to quantify the amount of the cytosolic enzyme LDH
released by damaged cells as an indicator of cellular toxicity.
PEGylated NPs (NP1−NP4) showed a safe cytotoxic proﬁle up
to a concentration of 1 mg/mL (Figure 3A). A slight increase in
cytotoxicity was noticed at a concentration of 2 mg/mL for
small-sized NPs (NP1−NP2), which could be ascribed to the
co-presence of negatively charged species and PEG macro-
molecules, as previously discussed. These peculiar surface
properties and/or their small size may have a diﬀerent eﬀect on
the cell surface at high concentrations. In the case of positively
charged NPs (NP5, NP6, NP7, Figure 3B), a marked cytotoxic
eﬀect was already evident at concentrations above 0.2 mg/mL,
most likely because of their strong electrostatic interaction with
the cell membrane and the consequent damage.28 Because of
their cytotoxicity, we decided not to use this set of NPs for
further study. Negatively charged NPs (NP8, NP9, NP10,
Figure 3C) showed no cytotoxicity for concentrations up to 0.5
mg/mL. Above 1 mg/mL, NPs showed a toxic eﬀect, which
may be due to the elevated uptake by podocytes (as conﬁrmed
afterward in the uptake tests). Cytotoxicity proﬁles of small
PEG-based NPs (NP1, NP2, NP11) are compared in Figure
3D. Whereas NP1 and NP2 showed a very similar trend, NP11
presented high cytotoxicity at a relatively low concentration
(>0.2 mg/mL), suggesting that the presence of positive charges
Table 1. NP Name, Emulsion Polymerization Conditions,
and Final Physicochemical Characteristics Obtained by DLS
name
surface
charge
surfmer content
(% w/w)
feeding
modality
av.
size
(nm) PDI
Z-pot
(mV)
NP1 (−) 20% PEGMA
and
5% SPMAK
MSSEP 37 0.02 −5.2
NP2 0 20% PEGMAa MSSEP 40 0.07 −9.6
NP3 0 20% PEGMA MSSEP 70 0.08 −3.2
NP4 0 9% PEGMA MSSEP 118 0.07 −2.4
NP5 + 20% MACC MSSEP 33 0.10 39.3
NP6 + 10% MACC MSSEP 75 0.09 42.8
NP7 + 5% MACC MSSEP 119 0.10 35.6
NP8 − 20% SPMAK MSSEP 33 0.11 −42.4
NP9 − 5% SPMAK BP 64 0.11 −37.8
NP10 − 3% SPMAK BP 117 0.14 −35.3
NP11 (+) 25% MACC and
11% PEGMA
MSSEP 38 0.18 25.2
aSodium dodecyl sulfate (SDS) (5% w/w) was also added to the
surfmer mixture to produce NP2.
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on NP surface, despite the co-presence of PEG chains, led to
cell membrane damage.
Cell Morphology and Cytoskeleton Rearrangement.
In addition to cytotoxicity tests, ﬂuorescence microscopy was
also necessary to evaluate the eﬀects of NP exposure on the
podocyte cytoskeleton, in particular actin ﬁber rearrangements,
as a sign of cellular stress.29,30
In fact, recent advances in podocyte biology have pointed out
how cell function is strongly dependent on the actin
cytoskeleton,31 and how actin ﬁber alterations may be a sign
of cell damage triggered by external chemical and biological
stimuli.30,31
PEGylated NPs do not seem to alter the actin ﬁber density
and orientation signiﬁcantly, even at high concentrations (up to
1 mg/mL) (NP1, Figure 4). On the other hand, negatively
charged NPs induced a marked actin rearrangement at high
concentrations (NP8, 1 mg/mL, Figure 4). In this case, the
actin density decreased around the nucleus, while accumulating
near the cell membrane. The ﬁber rearrangement was
associated with considerable NP uptake, demonstrated by the
presence of red spots (rhodamine-labeled NPs) within the
green phalloidin staining. At lower concentrations (<0.5 mg/
mL), negative NPs did not show substantial actin ﬁber
modiﬁcation, although NP internalization was still signiﬁcant.
Positively charged NPs clearly damaged the cell cytoskeleton at
all tested concentrations (0.05−1 mg/mL), which may be
ascribed to the eﬀect of a strong electrostatic interaction
between the nanomaterial and cell membrane before internal-
ization.28
NP Internalization. A well-established approach based on
the selective inhibition of endocytic pathways32 was employed
to investigate which NP uptake mechanisms were predom-
inantly used by podocytes, depending on the particle size and
surface chemistry (Figure 5).
We noticed that the uptake of PEGylated NPs (NP1, NP3,
NP4, Figure 5A(a)) was very limited when compared with that
of the other types of NPs (Figure 5A(b)) and that the
positively charged NP11 (Figure 5A(c)) showed the highest
uptake.
In the case of PEGylated NPs (Figure 5A(a)), a slight
decrease in NP uptake by increasing the particle size could be
appreciated in the range 30−120 nm. However, the eﬀect of
uptake inhibitors was not particularly marked, and this may be
due to the low percent uptake measured. Even the sodium
azide treatment, which should inhibit all energy-dependent
endocytic pathways, did not seem to have a statistically relevant
eﬀect.
On the other hand, negatively charged NPs (NP8, NP9,
NP10) showed a diﬀerent trend (Figure 5A(b)). The uptake
was enhanced; it was almost 3 times higher for the negatively
charged NP8 than that for the PEGylated NP1, although their
sizes were approximately the same.
When the particle size was varied, we noticed maximum
uptake at the intermediate average diameter (NP9, 64 nm),
Figure 2. Size distribution curves of NPs NP1−NP11 obtained by DLS analysis.
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which might be interpreted as a sign of a preferential endocytic
mechanism. In fact, caveolae typically appear as rounded
plasma membrane invaginations with diameters of 50−80 nm,33
although other works suggested that the pit diameter may not
be the limiting factor in the pathway selection of NP entry into
cells.34,35 Anyway, the clear inhibition eﬀect of Genistein
supported the hypothesis of a caveolin-dependent endocytosis,
whereas inhibition of clathrin-dependent uptake (chlorproma-
zine) showed a very limited eﬀect. The presence of an energy-
dependent endocytic mechanism was conﬁrmed by particle
uptake decrease after NaN3 treatment, which was apparent for
all negatively charged NPs (NP8, NP9, NP10), and in
particular, for particles larger than 30 nm. There was no
evidence of micropinocytosis (wortmannin inhibition). More-
over, the absence of eﬀects of baﬁlomycin A1 could indicate a
nonreceptor-mediated process,36 as expected.
Positively charged NP11 (Figure 5A(c)) showed a similar
trend to that in negative NPs but with much higher percent
uptake (about 6 times higher than that of PEG-NP and 2 times
higher than that of the negative NP). In this case, the
internalization seemed to be energy dependent and followed
preferentially a caveolin pathway. Notably, together with the
electrostatic interactions between this type of NPs and cell
membrane, adsorption of the negatively charged albumin
present in the FBS of the medium may also take place; this
could regulate NP interfacing with the cell membrane and
trigger an energy-dependent endocytosis.37 The eﬀect of NP
concentration on the internalization process was also assessed
(see the Supporting Information).
Figure 5B shows how the NP uptake followed a typical
endosomal pathway, particularly for negatively charged NPs.
Fluorescently labeled small PEGylated NPs (NP1, red) did not
show strong evidence of co-localization with the endosomal
compartments stained with lysotracker green (Figure 5B(a, b)).
This result may be due to the very limited internalization of
PEG-based NPs. On the other hand, small negatively charged
NPs (NP8) showed clear co-localization (orange color, Figure
5B(c, d)), which persisted even after 48 h.
Figure 3. LDH assay on murine podocytes (SV1) incubated with NP1−NP11 NPs (NP1−NP4 (A), NP5−NP7 (B), NP8−NP10 (C), NP1−NP2−
NP11 (D)) for 24 h, at concentrations from 0.01 to 2 mg/mL (Y axis: normalized cytotoxicity).
ACS Omega Article
DOI: 10.1021/acsomega.6b00423
ACS Omega 2017, 2, 599−610
603
In summary, we identiﬁed the surface properties of the NPs
(charge, PEGylation) as the dominant factors that aﬀect both
nanotoxicity and uptake on podocytes. Once cell−particle
interactions are guaranteed by their surface, the particle size
may also play a role in promoting speciﬁc endocytic pathways,
thus inﬂuencing the uptake.
In Vitro Release of Dexamethasone (DEX). Taking into
account the marked ability of podocytes to interact with
engineered polymeric NPs and internalize them according to
their physicochemical characteristics, we investigated the eﬀect
of drug-loaded NPs on podocyte repair, aiming at designing
novel polymeric nanocarriers, which may potentially target
podocytes in proteinuric diseases. The sustained therapeutic
eﬀects of nanoencapsulated drugs were demonstrated on
cultures of podocytes, whose damage was induced in vitro by
incubation with Adriamycin (doxorubicin hydrochloride) for 24
h.29,30 Damaged podocytes displayed shortened cell processes
and substantial remodeling of the actin cytoskeleton, with loss
of ﬁlament bundles and rounding of the cell shape30 (Figure 7).
DEX was chosen as the model drug for loading and release, ﬁrst
because it is a steroid with a proved eﬃcacy in repairing
podocytes38,39 (although literature data are generally referred to
the water-soluble DEX phosphate) and second because its low
molecular weight and high hydrophobicity are key character-
istics for eﬃcient encapsulation in these types of polyester-
based NPs,40 through interaction with the hydrophobic poly(ε-
caprolactone) core. A set of four diﬀerent NPs, having two
diﬀerent sizes (30 and 120 nm) and either PEGylated or
negatively charged (i.e., NP1, NP4, NP8, NP10), was chosen
for drug delivery tests. Positively charged NPs, including NP11,
were not taken into account because of their high cell toxicity.
Because high temperature and the presence of radicals were
unsuitable conditions for simultaneous drug loading during NP
synthesis, a postsynthesis swelling/diﬀusion encapsulation
method20 was optimized for this study (see the Methods
section). We obtained for each type of NP a target value of 50
± 1 μg of DEX encapsulated per mg of dry polymer (as
determined by high-performance liquid chromatography
(HPLC)). Drug release tests were carried out under sink
conditions in phosphate-buﬀered saline (PBS) at 37 °C.
Release proﬁles were followed by HPLC and are shown in
Figure 6. The drug release mechanism was purely diﬀusive, and
polymer degradation had no inﬂuence within the time scale of
the experiment.17,21,41 Clearly, small NPs (NP1, NP8)
presented a faster release due to their higher surface area per
mg of polymer compared to bigger NPs. In fact, NP4 and NP10
reached 97% release in 72 h, whereas NP1 and NP8 achieved
100% release in 24 h. Moreover, NPs having the same size but
diﬀerent surface properties showed a very similar release curve;
this result suggested that the DEX release mechanism was not
signiﬁcantly inﬂuenced by the presence of a PEG corona.
Although the NPs presented a relatively fast drug release
proﬁle (release curves plateaued at 24−72 h, depending on the
particle size), these results may be compatible with targeted
drug delivery to the kidneys, taking into account that a more
sustained delivery would be outweighed by the high turnover of
ﬂuids in kidney glomeruli (the renal blood ﬂow is
approximately 20% of the cardiac output, corresponding to a
glomerular ﬁltration rate of 1.2 L/min, and the total glomerular
ﬁltrate in 24 h is 50−60 times the volume of blood plasma in
adults42).
The eﬀect of DEX release by the NPs is summarized in
Figure 7. Cytoskeleton damage, triggered by Adriamicyn, was
Figure 4. Phalloidin staining (green) of ﬁlamentous actin in podocytes after 24 h NP exposure (NP1, NP8, NP11, red staining) at diﬀerent
concentrations (1, 0.5, and 0.05 mg/mL). Scale bar 20 μm.
ACS Omega Article
DOI: 10.1021/acsomega.6b00423
ACS Omega 2017, 2, 599−610
604
Figure 5. (A) Eﬀect of endocytosis inhibitors on 24 h NP uptake (NP1−NP3−NP4 (a), NP8−NP9−NP10 (b), NP1−NP8−NP11 (c), particle
concentration 0.5 mg/mL) (NC, negative control; CHLOR, chlorpromazine; GENIS, Genistein; WORT, Wortmannin; BAFIL, Baﬁlomycin A1;
NaN3, sodium azide). *P < 0.05, **P < 0.01. (B) Localization of rhodamine-labeled NPs (red) in relation to endolysosomes (green, LysoTracker
green) in SV1 podocytes. NP1 (PEGylated 37 nm, 0.5 mg/mL) and NP8 (sulfonate, 30 nm, 0.5 mg/mL) were incubated for 24 h (a, c) and their
localization visualized just after NP incubation and after 48 h (b, d). Scale bar 20 μm.
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highlighted by staining the actin ﬁbers (green phalloidin) and
observing that they were mostly localized in the proximity of
the cell membrane and their density was reduced within the cell
body and around the nucleus. When damaged cells were treated
with DEX-loaded PEGylated NPs (NP4, 20 μg/mL, loaded
with DEX 5% w/w) for 24 h, they started recovering the
normal orientation of actin stress ﬁbers (Figure 7A), a process
which was almost completed in 48 h. A very similar trend was
observed with negatively charged NPs (NP10, the same size as
NP4) but with a much higher internalization (see red spots
within the cytosolic space). On the other hand, at higher NP
concentrations (1 mg/mL), the toxic eﬀect (which perhaps was
also enhanced by the presence of a high drug concentration) of
NP10 as well as NP4 overwhelmed the repairing eﬀect of DEX.
Treatment with DEX-loaded small NPs NP1 and NP8 (size
37 and 33 nm, respectively) showed very similar results to
those obtained with the larger NP4 and NP10 (Figure 7B). At
1 mg/mL concentration, both PEGylated and negatively
charged NPs showed some toxic eﬀects, in particular a large
amount of NP8 were internalized. At a low concentration (0.02
mg/mL), the toxic eﬀect was reduced and DEX release
triggered recovery of actin ﬁber density and orientation. The
use of small NPs is clearly preferred for possible future in vivo
application because reduced size would facilitate drug
permeation through the kidney ﬁltration barrier, thus reaching
the podocyte layer more eﬃciently.43 In this case (Figure 7B),
we also noticed a marked recovery of actin ﬁber orientation and
density already after 24 h incubation with NP8, whereas with
Figure 6. DEX release from NPs NP1, NP4, NP8, and NP10 in PBS at
37 °C. Error bars indicate ±SD from experiments run in triplicate.
Figure 7. Podocytes were ﬁrst damaged by ADR, then treated for 24 and 48 h with DEX-loaded large NPs (NP4, NP10) (A) and small NPs (NP1,
NP8) (B), at two diﬀerent concentrations (1 mg/mL and 20 μg/mL). DEX (5% w/w), scale bar 20 μm.
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NP1, the eﬀect was pronounced only after 48 h. These results
may be ascribed to a much higher internalization of negatively
charged NPs, which allowed better intracellular release of DEX,
and therefore, an enhanced repairing eﬀect of the drug, whose
receptors reside in the cytosol.39
In Vitro Drug Testing in a 3D Co-culture System.
Nanodelivery of DEX was also successful in repairing damaged
co-cultures of endothelial cells and podocytes, which were
exploited as a tool for mimicking the glomerular ﬁltration
barrier in vitro.
The 3D co-culture model is based on an isoporous (1 μm
pore size) poly(ethylene terephthalate) membrane insert,
coated on both sides with collagen type IV, and ﬁnally covered
with podocytes and endothelial cells on the respective external
and internal sides18,19 (Figure 8A). The presence of the
membrane between the two cell types permits performing
separate assays in the two compartments and allows the
functional assessment of albumin permeability through the
membrane.
To establish whether this model could be useful in testing
our NP-based drug delivery system, the co-culture was
pretreated with Adriamycin to induce cellular damage and
increase albumin permeability. Afterward, the membrane was
incubated with DEX-loaded NP8 NPs, that is, the NP type
showing the best performance in terms of low cytotoxicity, high
uptake, DEX release, and podocyte-repairing eﬀect in a 2D
culture system.
NP concentrations were selected to achieve an optimal DEX
concentration range below 100 μM, that is, concentrations
already reached in humans after intravenous injection and oral
administration.44
NP treatment led to progressive reduction of albumin
permeability that was not observed with medium alone at 24
and 48 h of incubation (Figure 8B). In particular, a low
concentration of NPs (0.02 mg/mL, which encapsulated 5% w/
w of DEX, corresponding to 2 μM in the co-culture system)
achieved a reduction in albumin permeability, which was
comparable to the response to a high NP concentration (1 mg/
mL, corresponding to 100 μM in the co-culture system). This
may indicate either the presence of a concentration threshold,
above which cells respond in a similar way, or a more complex
balance between the DEX eﬀects and toxic eﬀects of the
polymeric nanomaterial at higher concentrations.
It is noteworthy that the incubation with these DEX-loaded
NPs did not return albumin permeability to its initial value
(prior Adriamycin treatment), but markedly reduced it below
the control values. This result could be ascribed to the role of
DEX in stimulating better cellular layer organization, with a
consequent decrease in the membrane pore size/number.
■ CONCLUSIONS
Engineered polymeric NPs of tuneable size and surface
properties were successfully produced and used to evaluate
their interactions with kidney podocytes in vitro. The
cytotoxicity, uptake, and cytoskeleton stress were markedly
dependent on the particle size, surface charge, and PEG corona.
Damaged podocytes were successfully repaired with controlled
nanodelivery of DEX, in view of developing new kidney-speciﬁc
nanotherapeutics. A 3D co-culture system based on endothelial
cells and podocytes was also employed to study the
mechanisms of NP interaction with glomerular cells and the
repair of a podocyte−endothelium membrane, designed to
mimic the kidney ﬁltration barrier in vitro.
■ METHODS
NP Synthesis, Drug Loading, and in Vitro Release.
Materials, synthesis of the HEMA-CL3 macromonomer, and
synthesis of the ﬂuorescent HEMA-RhB monomer are reported
in the Supporting Information.
Synthesis of Polyester-Based NPs. NP synthesis was
carried out in a three-neck ﬂask, equipped with a condenser,
containing 49 mL of distilled water; the system was purged
through repeated vacuum−nitrogen cycles and kept at 80 °C
through the use of an external oil bath. Depending on the target
particle size and surface charge, diﬀerent surfmers (PEGMA,
SPMAK, and MACC), macromonomer/surfmer mass ratios,
and either BEP or MSSEP were used, as summarized in Table
1. In BEP, the macromonomer, HEMA-CL3, and the surfmer
were loaded together into the reactor, whereas in MSSEP, the
water-soluble surfmer was added into the reactor, whereas the
Figure 8. (A) Sketch of the 3D co-culture system designed to mimic glomerular ﬁltration barrier in vitro. (B) Percent increase of albumin (ALB)
permeability following Adriamycin treatment (ADR), and recovery by 24 and 48 h of incubation with standard medium (MED) and DEX-loaded
NP8 at a high concentration (DEX-H; NP8 1 mg/mL + DEX 5% w/w, corresponding to 100 μM) and a low concentration (DEX-L; NP8 0.02 mg/
mL + DEX 5% w/w corresponding to 2 μM).
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hydrophobic HEMA-CL3 macromonomer was fed using a
syringe pump (model NE 300; New Era Pump System, the ﬂow
rate was changed for each sample to maintain the feeding equal
to 1 h).17 One gram of total monomer mixtures (macro-
monomer and surfmer) was used for all reactions, unless
speciﬁcally noted; 0.1% w/w HEMA-RhB was also added when
ﬂuorescently labeled NPs were required for biological experi-
ments.
KPS (20 mg) was used as the initiator for synthesizing
negatively charged and PEGylated NPs, whereas 20 mg of
AAPH was employed for positively charged NPs. In all cases,
the reaction was carried out for 3 h, and before any further use,
NPs were dialyzed (3500 Da cutoﬀ membranes) against PBS
buﬀer (10 mM) to remove any possible impurities. The particle
size distribution, average size, PDI, and Z-potential of the ﬁnal
products were evaluated via DLS (Malvern Zetasizer Nano).
TEM samples of selected NP latexes were investigated on a
Zeiss EFTEM Leo 912AB transmission electron microscope
working at 80 kV. The sample was prepared by placing a 5 μL
drop of NP colloidal suspension on a Formvar/carbon-coated
copper grid and was dried overnight. Digital images were
acquired by a charge-coupled device Esi Vision Proscan camera.
Drug Loading and in Vitro Release. NP latexes (NP1,
NP8, NP4, NP10) were concentrated up to 5% w/w under a
rotavapor, and DLS analysis conﬁrmed the absence of
aggregation. DEX was dissolved in dimethyl sulfoxide
(DMSO) (20 mg/mL) under gentle magnetic stirring at
room temperature. The two phases (NP latex and drug in
DMSO) were injected axially into a poly(tetraﬂuoroethylene)
mixing device20 at a ﬂow rate of 30 and 5 mL/min, respectively.
DEX-loaded NPs were collected from the mixer outlet, and the
absence of DEX aggregates was conﬁrmed by DLS.
The drug-loading eﬃciency was evaluated by placing drug-
loaded NP latexes in centrifugal ﬁlters (Amicon Ultra, 100 kDa
cutoﬀ), which were centrifuged at 4500 rpm for 15 min to
separate the NPs from the supernatant and the free drug. The
ﬁnal concentration of free drug in the supernatant was
calculated by HPLC analysis.23
Release studies were conducted via HPLC by dialyzing 3 mL
of DEX-loaded NPs against 200 mL of PBS buﬀer at 37 °C with
Slyde A Lyzer Dialysis cassettes (Thermo Scientiﬁc, 3500 Da
cutoﬀ). At selected times, small aliquots (50 μL) were
withdrawn and replaced with an equal volume of PBS. These
aliquots were dried under a nitrogen stream and extracted with
a ﬁxed volume of acetonitrile under vortex mixing. After
centrifugation at 4000 rpm for 10 min, the supernatant was
injected into the HPLC system (Agilent 1200 series) equipped
with a UV−vis detector (λ = 250 nm); the mobile phase was
composed of water and acetonitrile (70/30 v/v) under isocratic
conditions at a ﬂow rate of 1.5 mL/min (DEX elution time 10
min).
Before in vitro experiments, 3 mL of the selected DEX-
loaded NPs were dialyzed against 200 mL of PBS to remove
solvent and impurities from the formulations.
LDH Cytotoxicity. The NP cytotoxicity was measured
using an LDH-Cytotoxicity Colorimetric Assay Kit (BioVision
Incorporated), which was used according to supplier’s protocol
(experimental details are reported in the Supporting
Information).
Fluorescence Microscopy Examination. Conditionally
immortalized murine kidney podocytes SV1 (CLS Cell Line
Service Ltd, Eppelheim, Germany) were cultured on coverslips
and ﬁxed with 4% of paraformaldehyde at room temperature
for 10 min. After washing, cells were permeabilized with 0.3%
of Triton in PBS for 5 min and incubated with 1% of bovine
serum albumin in PBS at room temperature for 30 min.
Phalloidin-FITC (Sigma-Aldrich) at 1:100 dilution together
with DAPI at 1:1000 dilution (Sigma-Aldrich) was added, and
the cells were incubated for 1 h. After 3 times washing with
PBS, the cells were mounted with Fluorsave aqueous mounting
medium (Merck, Milano, Italy). Images were acquired using a
Zeiss AxioObserver microscope equipped with a high-
resolution digital videocamera (AxioCam, Zeiss) and an
Apotome system for structured illumination, and recorded by
the AxioVision software, version 4.8.
NP Uptake. SV1 cells (6000−8000 per well) were plated on
a 96-well black plate and cultured at 37 °C without γ-interferon
for 3−4 days. Then, the culture medium was replaced by
medium containing diﬀerent endocytosis inhibitors (Chlorpro-
mazine 10 μg/mL; Genistein 200 μM; Wortmannin 100 nM;
Baﬁlomycin A1 200 nM; Sodium azide 10 mM, all purchased
from Sigma), which were preincubated with the cells for 30
min. After 30 min preincubation, NP1−NP11 were added at a
concentration of 0.5 mg/mL, alone or together with the
inhibitors, and incubated with cells for 24 h. At the end of
incubation, the supernatants were removed, and the cells were
thoroughly washed thrice with PBS. The intracellular NP was
measured using SAFAS spectrophotometry at an excitation
wavelength of 540 nm and an emission wavelength of 584 nm.
Janus Green cell normalization stain was used to adjust the cell
plating diﬀerence among the wells. NP−lysosome co-local-
ization was characterized by incubating the cells with
LysoTracker green (Life technologies) at a concentration of
666 nM together with Hoechst 33342 (Life technologies) at a
concentration of 5 μg/mL in culture medium for 1 h. At the
end of incubation, the staining solution was replaced with fresh
medium without phenol red, and the cells were observed using
a Zeiss AxioObserver microscope.
DEX Release on Podocytes. SV1 cells (20 000) were
plated on a 35 mm Petri dish containing four cell culture
coverslips and cultured at 37 °C without γ-interferon for 3−4
days. Afterwards, cells were incubated with 0.8 μM Adriamycin
(ADR, Sigma-Aldrich) in cell culture medium for 24 h. After 24
h incubation, ADR was replaced by fresh medium (as the
control group) or medium with a diﬀerent concentration of
NPs loaded with DEX and incubated for another 24 or 48 h.
Cells were ﬁnally washed thrice with PBS and characterized by
ﬂuorescence microscopy, as described above.
Co-Culture System and Assessment of Permeability.
Preparation of the three-dimensional podocyte−endothelial cell
co-cultures and protein permeability assessment were carried
out according to a previously reported procedure.19 Exper-
imental conditions for Adriamicin treatment and NP incubation
are described in the Supporting Information.
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